Concord Medical Services Holdings Limited (CCM) AI Stock Analysis

Concord Medical Services Holdings Limited, based in Beijing, China, operates a network of radiotherapy and diagnostic imaging centers through Network and Hospital segments. Its Network segment provides external beam radiotherapy, gamma knife radiosurgery, and computed tomography imaging, alongside clinical support, equipment leasing, and teleconsultation. The company also sells medical equipment and delivers medical information technology solutions. In addition, Concord Medical operates specialty cancer hospitals offering comprehensive oncology care including radiotherapy, chemotherapy, diagnostic imaging, and surgical procedures. As of December 31, 2021, the company operated 16 cooperative centers across 13 hospitals.

Between FY2020 and FY2025, revenue grew at a 5-year CAGR of 15.6%. Revenue reached $537.4M in FY2023 before falling 28.6% to $384.0M in FY2024. In FY2025, revenue rebounded 19.9% to $460.5M, and gross margin reached 5.6% compared to -20.6% in FY2024. Operating margin was -52.0% in FY2025, compared to -138.6% in the prior year. Net income was -$92.8M in FY2025, compared to -$308.2M in FY2024. For the trailing twelve months ended March 31, 2026, quarterly revenue growth rose 57.4% year-over-year, while TTM net margin was -20.2% and EPS was -$3.03.

As of March 31, 2026, Concord Medical held $297.8M in cash and short-term investments against total debt of $3.63B, resulting in net debt of $3.34B. Total assets stood at $6.55B, but shareholders' equity was -$2.10B, reflecting negative equity. The company's current ratio was 0.48. In FY2025, capital expenditures were $91.3M, while operating cash flow was -$201.8M and free cash flow was -$293.2M. Over the past five years, the share count declined 99.9%.

At a last close of $3.63 on October 16, 2026, Concord Medical carries a market capitalization of $15.8M and an enterprise value of $514.8M. The stock trades at a forward P/E of 11.3x, compared to a median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 0.0x versus the peer median of 4.1x, and its EV-to-revenue stands at 7.5x. Over the past year, CCM fell 38.1%, while the S&P 500 benchmark gained 16.8%. Over five years, the stock dropped 86.8% compared to an 83.0% gain for the S&P 500.

Wall Street analysts maintain a mean price target of $1.20 for Concord Medical, indicating a 66.9% decline from the last close of $3.63. Over the last four quarters, the company recorded 0 EPS beats. In trailing twelve months results, diluted EPS stood at -$3.03. Ownership data shows insiders hold 25.6% of shares, institutional investors own 1.3%, and short interest represents 0.8% of the float.

This page is an AI-written research summary of Concord Medical Services Holdings Limited (CCM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CCM income statement, CCM balance sheet, CCM key metrics, CCM chart. See the CCM stock overview for the latest quote and news.